Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 5/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 8/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16156155 | 0.87 | KMT2A (0.60) | KMT2APPARGHTR2AHTR2CPPARD | |
| SCHEMBL16234651 | 0.85 | HTR2C (0.55) | KMT2APPARGHTR2AHTR2CFABP4 | |
| SCHEMBL2014724 | 0.85 | HTR2C (0.55) | KMT2APPARGHTR2AHTR2CFABP4 | |
| SCHEMBL418370 | 0.81 | P2RX7 (0.50) | PPARGHTR2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL14485186 | 0.81 | KMT2A (0.57) | KMT2APPARGHTR2AHTR2CPPARD | |
| SCHEMBL30103437 | 0.81 | KMT2A (0.62) | KMT2APPARGPPARDPPARA | |
| SCHEMBL4234811 | 0.81 | KMT2A (0.62) | KMT2APPARGPPARDPPARA | |
| SCHEMBL418013 | 0.80 | KMT2A (0.60) | KMT2APPARGHTR2AHTR2CPPARD | |
| SCHEMBL28607801 | 0.80 | KMT2A (0.60) | KMT2APPARGPPARDPPARA | |
| SCHEMBL5537950 | 0.80 | KMT2A (0.60) | KMT2APPARGHTR2AHTR2CPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107250133-B | Hydroxyalkyl piperazine derivatives as CXCR3 receptor modulators | 爱杜西亚药品有限公司 | 2020-09-15 | — | — | CN | disclosed |
| EP-3245203-B1 | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-14 | — | — | EP | disclosed |
| US-10053457-B2 | Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-08-21 | — | — | US | disclosed |
| WO-2018065607-A1 | CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN RELATED PEPTIDASE 6 (KLK6) | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2018-04-12 | — | — | WO | disclosed |
| EP-3305781-A1 | CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN-RELATED PEPTIDASE 6 (KLK6) | Deutsches Krebsforschungszentrum (DE) | 2018-04-11 | — | — | EP | disclosed |
| US-20180009799-A1 | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-11 | — | — | US | disclosed |
| EP-3245203-A1 | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016113344-A1 | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-21 | — | — | WO | disclosed |
| US-8586589-B2 | Piperidine and piperazine phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-7358248-B2 | Substituted amino carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| EP-1814869-A2 | SUBSTITUTED AMINO ACIDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007075895-A2 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| CN-1812979-A | Substituted aminocarboxylic acids as inhibitors of protein tyrosine phosphatase-1B | INST PHARM DISCOVERY INC (US) | 2006-08-02 | — | — | CN | disclosed |
| US-20060122223-A1 | Substituted amino carboxylic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC | 2006-06-08 | — | — | US | disclosed |
| WO-2006055725-A2 | SUBSTITUTED AMINO ACIDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1622886-A2 | SUBSTITUTED AMINO CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040266789-A1 | Substituted amino carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2004-12-30 | — | — | US | disclosed |
| WO-2004099171-A2 | SUBSTITUTED AMINO CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053457-B2 | Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators | CXCR3, CXCR1, CXCR2 | KMT2A 3356/4885PPARG 318/4885HTR2A 258/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | KMT2A 2855/4885PPARG 1854/4885HTR2A 457/4885 |
| US-20180009799-A1 | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | CXCR3, CXCR1, CXCR2 | KMT2A 3356/4885PPARG 318/4885HTR2A 258/4885 |
| US-20060122223-A1 | Substituted amino carboxylic acids | PTPRS, PTPRO, PTPRJ | KMT2A 2273/4885PPARG 328/4885HTR2A 1870/4885 |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | KMT2A 1129/4885PPARG 1540/4885HTR2A 408/4885 |
| US-20040266789-A1 | Substituted amino carboxylic acids | PTPRS, PPM1B, PTPRO | KMT2A 2369/4885PPARG 448/4885HTR2A 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.